Review of IL-17 inhibitors for psoriasis.


BACKGROUND The development of biologic agents directed against distinct cytokines and receptors has advanced the therapeutic options available for psoriasis patients. Evidence from preclinical studies suggests that IL-17 may contribute to the pathogenesis of psoriasis. OBJECTIVE The objective was to review the safety and efficacy profile for each IL-17 inhibitor by evaluating phase III clinical trial data. METHODS We reviewed the results of phase III clinical trials for the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab. RESULTS At week 12, the proportion of patients reaching Psoriasis Area and Severity Index (PASI 75) was above 60% for the most efficacious dose of each agent with favorable and comparable safety profiles. The most commonly reported adverse events were nasopharyngitis, headache, and upper respiratory tract infection. CONCLUSIONS The clinical improvement among psoriasis patients on IL-17 inhibitors is similar or superior to the improvement seen with commercially produced biologic agents available accompanied by a favorable short-term safety profile. The results of the phase III trials indicate that IL-17 inhibitors are effective therapeutic options for psoriasis patients.

DOI: 10.1080/09546634.2017.1395796

Cite this paper

@article{Amin2017ReviewOI, title={Review of IL-17 inhibitors for psoriasis.}, author={Mina Amin and Kavita Darji and Daniel J No and Tina Bhutani and Jashin J. Wu}, journal={The Journal of dermatological treatment}, year={2017}, pages={1-6} }